IL-2

IL-2

IL-2 Overview

Molecule Name
Interleukin-2
Synonyms
IL2,TCGF,lymphokine,Interleukin 2
Drug Development Progress
Drugs in Clinical Trials43
Approved Drugs2
Highest Development StageApproved
Target Synonym
T-cell growth factor,IL2,Interleukin 2,T Cell Growth Factor,Aldesleukin,IL-2,TCGF,Involved In Regulation Of T-Cell Clonal Expansion,Interleukin-2,Lymphokine
Background
Interleukin-2 (IL-2) is an interleukin, a type of cytokine immune system signaling molecule, which is a leukocytotrophic hormone that is instrumental in the body's natural response to microbial infection and in discriminating between foreign (non-self) and self. IL-2 mediates its effects by binding to IL-2 receptors, which are expressed by lymphocytes, the cells that are responsible for immunity. Mature human IL-2 shares 56% and 66% aa sequence identity with mouse and rat IL-2, respectively. Human and mouse IL-2 exhibit crossspecies activity. The receptor for IL-2 consists of three subunits that are present on the cell surface in varying preformed complexes. IL-2 is also necessary during T cell development in the thymus for the maturation of a unique subset of T cells that are termed regulatory T cells (T-regs). After exiting from the thymus, T-Regs function to prevent other T cells from recognizing and reacting against "self antigens", which could result in "autoimmunity". T-Regs do so by preventing the responding cells from producing IL-2. Thus, IL-2 is required to discriminate between self and non-self, another one of the unique characteristics of the immune system.

IL-2 Product List

Species
  • Human(9)
  • Cynomolgus(2)
  • Mouse(2)
  • Rat(1)
Tag
  • Tag Free(5)
  • His Tag(4)
  • His Tag & Avi Tag(3)
  • Fc Tag(1)
  • Fc Tag & Avi Tag(1)
Host
  • HEK293(10)
  • E. coli(4)
Conjugate
  • Unconjugated(10)
  • Biotin-labeled(4)
Grade
  • RUO(10)
  • GMP(3)
  • PG (pre-GMP)(1)
Low Endotoxin
  • Yes(1)
  • No(13)
MoleculeCat. No.Product NameSpeciesHostStructurePurityActivitySize&Price
IL-2
CytoPak GMP Human IL-2 Protein
Human
E. coli
SDS-PAGE
CELL BASE
Inquiry
15X10^6IU
IL-2
Human IL-2 Superior Stable Protein, premium grade
Human
E. coli
SDS-PAGE
CELL BASE

$229.00

1X10^6IU
IL-2
Human IL-2 Protein, Tag Free (MALS verified)
Human
HEK293
MALSSDS-PAGE
CELL BASE

$50.00

20ug
IL-2
GMP Human IL-2 Protein (Liquid)
Human
E. coli
MSSDS-PAGE
CELL BASE

$540.00

5X10^6IU
IL-2
GMP Human IL-2 Protein
Human
E. coli
MSSDS-PAGE
CELL BASE

$155.00

1X10^6IU
IL-2
Cynomolgus IL-2 Protein, His Tag
Cynomolgus
HEK293
SDS-PAGE
ELISASPR

$360.00

100ug
IL-2
Avitag
IL2-C82E4
Biotinylated Cynomolgus IL-2 Protein, His,Avitag™ (MALS verified)
Cynomolgus
HEK293
MALSSDS-PAGE
ELISA

$360.00

25ug
IL-2
Human IL-2 Protein, Fc Tag, low endotoxin (Mass Spec & MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISABLI

$360.00

100ug
IL-2
Human IL-2 Protein, His Tag
Human
HEK293
SDS-PAGE
ELISABLI

$325.00

100ug
IL-2
Avitag
IL2-H82E5
Biotinylated Human IL-2 Protein, His,Avitag™ (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISA

$415.00

25ug
You Have Viewed 1-10 Of 14 Results
  • 1
  • 2

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Darleukin/fibromunL19-IL-2/ L19-TNF-αPhase 3 ClinicalPhilogen Spa
Basal Cell Nevus Syndrome; Carcinoma, Basal Cell; Carcinoma, Merkel Cell; Carcinoma, Squamous Cell; Melanoma; Sarcoma, Kaposi
Details
Bifikafusp alfaL19-IL-2Phase 3 ClinicalPhilogen Spa
Adenomatous Polyposis Coli; Carcinoma, Basal Cell; Carcinoma, Non-Small-Cell Lung; Melanoma; Pancreatic Neoplasms; Solid tumours
Details
IBI-363IBI-363Phase 3 Clinical
Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Lymphoma; Melanoma; Mucosal Melanoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms
Details
EQ-101EQ101; EQ-101; BNZ132-1-40; BNZ-1; BNZ132-1; BNZ-01Phase 2 ClinicalBioniz Therapeutics Inc
Alopecia; Alopecia Areata; Leukemia, Large Granular Lymphocytic; Lymphoma, T-Cell, Cutaneous
Details
umitrelimorgene autodencelITI-1000Phase 2 ClinicalImmunomic Therapeutics Inc
Glioblastoma
Details
S-95007S-95007Phase 2 ClinicalLaboratoires Servier
Immune System Diseases; Inflammation
Details
SIM-0278ALM-223; SIM0278Phase 2 ClinicalSimcere Pharmaceutical Group Ltd
Autoimmune Diseases; Dermatitis, Atopic; Lupus Erythematosus, Systemic; Lupus Nephritis
Details
ImneskibartBD-8; AU-007; BDG-8Phase 2 ClinicalBiolojic Design Inc
Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Neoplasms; Skin Melanoma; Solid tumours
Details
XTX-202XTX-202Phase 2 ClinicalXilio Development Inc, Xilio Therapeutics Inc
Carcinoma, Renal Cell; Melanoma; Solid tumours
Details
STK-012STK-012Phase 2 ClinicalSynthekine Inc
Carcinoma, Non-Small-Cell Lung; Solid tumours
Details
EGL-001EGL-001Phase 2 ClinicalEgle Therapeutics
Neoplasms; Solid tumours
Details
STI-7349STI-7349; ILKN421HPhase 2 ClinicalThe Fourth Affiliated Hospital, Zhejiang University School Of Medcine
Carcinoma, Non-Small-Cell Lung; Solid tumours
Details
LAT-010LAT010; LAT-010Phase 2 ClinicalLatticon Antibody Therapeutics Inc
Neoplasm Metastasis; Solid tumours
Details
COYA-302COYA 302; COYA-302; COYA302Phase 2 ClinicalCoya Therapeutics Inc
Amyotrophic Lateral Sclerosis; Frontotemporal Dementia; Parkinson Disease
Details
KB-707KB707; KB-707Phase 2 ClinicalKrystal Biotech Inc
Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Melanoma; Neoplasms; Skin Melanoma; Solid tumours
Details
REGN-10597REGN-10597Phase 2 ClinicalRegeneron Pharmaceuticals Inc
Carcinoma, Renal Cell; Melanoma; Neoplasms; Solid tumours
Details
SAR-444336SAR-444336; THOR-809Phase 2 ClinicalSanofi
Colitis, Microscopic; Inflammation
Details
COYA-301COYA-301Phase 2 ClinicalCoya Therapeutics Inc
Alzheimer Disease
Details
SaltikvaMDB401BPhase 2 ClinicalSalspera LLC, Sunshine Lake Pharma
Pancreatic Neoplasms
Details
Igrelimogene litadenorepvecPM-1016; PM1016; TILT-123Phase 2 ClinicalTilt Biotherapeutics Ltd
Carcinoma, Hepatocellular; Fallopian Tube Neoplasms; Lung Neoplasms; Melanoma; Ovarian Neoplasms; Peritoneal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck
Details
LMBP2-specific TCR-T cell therapy (TCRCure Biopharma)Phase 2 ClinicalTcrcure Biopharma Ltd
Nasopharyngeal Carcinoma
Details
Interleukin-2 gene therapy (St Jude Children's Research Hospital)Phase 1 ClinicalNational Cancer Institute, St. Jude Children'S Research Hospital
Neuroblastoma
Details
T20KT-20KPhase 1 ClinicalCyxone
Multiple Sclerosis
Details
ODC-IL2ODC-IL-2; ODC-IL2; ODC-1L2Phase 1 ClinicalTrutino Biosciences Inc
Neoplasms; Solid tumours
Details
Etakafusp alfaAB-248Phase 1 ClinicalAsher Biotherapeutics Inc
Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Melanoma; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms
Details
ASP-1012VET2-L2; ASP-1012; ASP1012Phase 1 ClinicalKaliVir Immunotherapeutics Inc
Solid tumours
Details
TEV-278TEV-278; TEV-‘278Phase 1 ClinicalTeva Pharmaceutical Industries Ltd
Neoplasms
Details
HM-16390HM-16390; HM16390Phase 1 ClinicalHanmi Pharmaceutical Co Ltd
Solid tumours
Details
IL2 CD25 fusion protein (Bristol-Myers Squibb)Phase 1 ClinicalUniversity Of Miami
Autoimmune Diseases
Details
EGL-003EGL-003Phase 1 ClinicalEgle Therapeutics
Autoimmune Diseases; Dermatitis, Atopic; Neoplasms
Details
KYS-202003-AKYS-202003-A; KYS202003APhase 1 ClinicalJiangsu Kanion Pharmaceutical Co Ltd
Solid tumours
Details
M5A-IL2 ImmunocytokineM5A-ICKPhase 1 ClinicalCity Of Hope National Medical Center, National Cancer Institute
Breast Neoplasms; Colorectal Neoplasms
Details
DF-6215DF6215; DF-6215Phase 1 ClinicalDragonfly Therapeutics Llc
Solid tumours
Details
DodekinPhase 1 ClinicalPhilogen Spa
Solid tumours
Details
TEV-56278TEV-56278Phase 1 ClinicalTeva Pharmaceutical Industries Ltd
Melanoma; Neoplasms; Solid tumours
Details
AttIL2-T cell therapyPhase 1 ClinicalThe University Of Texas MD Anderson Cancer Center
Osteosarcoma; Sarcoma; Soft Tissue Neoplasms
Details
Autologous tumor-infiltrating lymphocyte cells therapy (Hervor Therapeutics)HV-101; HV101Phase 1 ClinicalHangzhou Houwu Biomedical Technology Co Ltd, Hervor Therapeutics, Tcrcure Biopharma Ltd
Solid tumours
Details
KY-0118KY-0118; KY0118Phase 1 ClinicalNovatim Immune Therapeutics (Zhejiang) Co Ltd
Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Melanoma; Neoplasms; Pancreatic Neoplasms; Solid tumours
Details
VIS171VIS-171; VIS171Phase 1 ClinicalVisterra Inc
Alopecia Areata; Autoimmune Diseases; Glomerulosclerosis, Focal Segmental; Lupus Erythematosus, Systemic
Details
MK-1484MK-1484; SP-482Phase 1 ClinicalMerck & Co Inc, Sutro Biopharma Inc
Solid tumours
Details
CUG-252CUG-252Phase 1 ClinicalCugene Inc
Autoimmune Diseases; Lupus Erythematosus, Systemic
Details
RS-2102RS2102Phase 1 ClinicalReistone Biopharma Co Ltd
Dermatitis, Atopic
Details
BNT-153BNT-153Phase 1 ClinicalBiontech Se
Solid tumours
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
PropagermaniumSK-818; SK-818CApprovedSanwa Kagaku Kenkyusho Co LtdSerocionJapanHepatitis BSanwa Kagaku Kenkyusho Co Ltd1994-01-01
Hepatitis B
Details
ThalidomideNSC-66847; NSC-527179; K-17; FPF-300; FPF300ApprovedCelgene CorpTalizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, ThaledMainland ChinaLeprosy, Lepromatous; Multiple MyelomaChangzhou Pharmaceutical Factory1982-01-01
Acquired Immunodeficiency Syndrome; Adenocarcinoma, Clear Cell; Adenoma, Islet Cell; Amyotrophic Lateral Sclerosis; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Anemia, Sideroblastic; Angiodysplasia; Appendiceal Neoplasms; Arachnoiditis; Arteriovenous Malformations; Axial Spondyloarthritis; beta-Thalassemia; Burning Mouth Syndrome; Carcinoid Tumor; Carcinoma, Adenosquamous; Carcinoma, Hepatocellular; Cholangitis, Sclerosing; Colorectal Neoplasms; Cough; Endometrial Neoplasms; Endometriosis; Epilepsy; Erythema Nodosum; Gastric Antral Vascular Ectasia; Gastrointestinal Hemorrhage; Genetic Diseases, Inborn; Glioma; Graft vs Host Disease; Head and Neck Neoplasms; Hemoglobinopathies; HIV Infections; HIV Wasting Syndrome; Hodgkin Disease; Hormone-Resistant Prostate Neoplasms; Hypertension, Portal; Idiopathic Pulmonary Fibrosis; Kidney Neoplasms; Leiomyosarcoma; Leprosy, Lepromatous; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelomonocytic, Chronic; Liver Neoplasms; Lung Neoplasms
Details
Customer Reviews
  • JC2024-12-11
    This product was ordered for the purpose of culturing immune cells; these cells were in turn used in downstream experiments to assess the efficacy and toxicity of ADCs. This product was delivered punctually and the labels were very clear. There is more than sufficient volume, and it worked seamlessly compared to products tried in the past. It is highly recommended for other users who work with immune cells.
  • K***s2023-05-18
    My lab utilized this antibody as an analyte to prove/disprove binding capability to one of our proprietary antibodies. In addition to antibody screening, we also used it as a positive control to compare efficacy of in house IL2. We used it on Octet, which works with BLI technology to determine binding affinities. We appreciate the quick shipping and delivery of this product as our assays needed to be completed within a specific timeline.